Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/26087
Başlık: | Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor? |
Diğer Başlıklar: | Majör depresif bozukluk tedavisinde yanıt ve remisyona etki eden faktörler: Sosyal uyum belirleyici olabilir mi? |
Yazarlar: | Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. 0000-0003-0297-846X Sivrioğlu, Yusuf Kırlı, Selçuk Akkaya, Cengiz Eker, Salih Saygın Özkaya, Güven Q-9477-2019 A-4421-2016 14062563200 14019745700 14061855100 14019347700 16316866500 |
Anahtar kelimeler: | Major depression Pharmacotherapy Reboxetine Remission Reply Sertraline Social adaptation Venlafaxine Reboxetine Efficacy Tolerability Venlafaxine Sertraline Pharmacology & pharmacy Psychiatry |
Yayın Tarihi: | Mar-2009 |
Yayıncı: | Küre İletişim |
Atıf: | Sivrioğlu, Y. vd. (2009). "Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?". Klinik Psikofarmakoloji Bülteni, 19(Supplement 1), S137-S139. |
Özet: | Objective: Major depression is a frequent disorder successfully treated with antidepressants (1). Response and remission depend on the type of pharmacological treatment as well as patient characteristics. The aim of the study is to evaluate the factors influencing response and remission rates. Method: Data from 4 studies (2-4) sharing the same methodology is pooled and reanalyzed. Subjects with major depression were assigned to reboxetine, sertraline or venlafaxine XR treatment in an open label fashion. The initial dose of reboxetine and venlafaxine XR were 4mg/day and 75mg/day respectively. The dose was increased at the second week to 8mg/day for reboxetine and 150mg/day for venlafaxine XR. Sertraline dose was 50mg/day throughout the study. Subjects were assessed at baseline, 2 weeks, 4 weeks, 7 weeks and 10 weeks with Hamilton Depression Rating Scale (HDRS) (5), Hamilton Anxiety Rating Scale (HARS) (6) and, Social Adaptation Self-Evaluation Scale (SASS) (7). Results: Characteristics of the study population (n=149) are summarized in Table 1. The response and remission rates were 67.8% (n=101) and 55% (n=82) respectively. Total number of episodes, time since first episode, baseline HDRS and HARS scores were significantly lower and baseline SASS score was significantly higher in responders and remitters when compared to non-responders and non-remitters respectively (Table 2). Logistic regression analyses where response and remission were dependent variables and, treatment arm, gender, age, duration of last episode, number of past episodes,.time since first episode and baseline HDRS, HADRS and SASS scores were independent variables revealed that baseline SASS score was the only factor significantly increasing the odds of response (p=0.035 OR:1.06 %95 CI: 1.005-1.131) and remission (p=0,019 OR:1,07 %95CI: 1,012-1,140). Conclusion: Our findings suggest that baseline social adaptation may have a modest impact on response and remission but other factors not evaluated in our study may also influence the rates of response and remission. |
URI: | http://hdl.handle.net/11452/26087 |
ISSN: | 1017-7833 |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.